Long-Term Survivorship Rates for First-Line Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (aRCC) Patients Achieving Objective Response (OR) with Nivolumab plus Ipilimumab (N+I)
Ipilimumab;Nivolumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Long-Term Survivorship Rates for First-Line Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (aRCC) Patients Achieving Objective Response (OR) with Nivolumab plus Ipilimumab (N+I) ### Output: Ipilimumab;Nivolumab